Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab European Patent17753704.0Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab China201780011505Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Canada3014674Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Read more about Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab Australia2017221268Filed on 2017-02-14
Chimeric Antigen Receptors Containing Glypican 2 Binding Domains Read more about Chimeric Antigen Receptors Containing Glypican 2 Binding Domains European Patent20751027.2Filed on 2020-07-17
FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME Read more about FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME US Application 17/689,698Filed on 2022-03-08
METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY Read more about METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY US Application 17/682,655Filed on 2022-02-28
CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY Read more about CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY Hong Kong62022051308.4Filed on 2020-03-13
Chimeric Antigen Receptors Targeting B-cell Maturation Antigen Read more about Chimeric Antigen Receptors Targeting B-cell Maturation Antigen South Korea2022-7005825Filed on 2022-02-21
Chimeric Antigen Receptors Targeting CD-19 Read more about Chimeric Antigen Receptors Targeting CD-19 Israel291292Filed on 2022-03-13